Drug intelligence / Profile preview

CVD-1301.A02

Development stage: Preclinical
Lead developer: Hangzhou Converd

Overview

CVD-1301.A02 is a drug candidate currently in preclinical development by Hangzhou Converd Co., Ltd. It is being investigated for its potential use in treating Adenoviridae Infections. While the specific mechanism of action for CVD-1301.A02 is not publicly detailed, its development by a company focused on oncolytic viruses and cancer immunotherapies suggests a potential biological or viral-based approach, though its indication for infectious diseases points towards an antiviral function.

Beyond the preview

Go deeper on CVD-1301.A02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVD-1301.A02.

Explore the full profile